Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR (TAKP34) Price & Analysis

Q: Is Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR overvalued?

According to Wall Street analysts Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Which hedge fund is a major shareholder of Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR?

Currently, no hedge funds are holding shares in BR:TAKP34

― Followers

TAKP34 Stock Chart & Stats

R$99.07

R$1.30(1.33%)

Sep 29, 2026

―

Day’s Range― - ―

52-Week RangeR$65.09 - R$100.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)36.00

Market Cap

R$304.64B

Enterprise ValueR$274.78K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.12

Next Earnings

Oct 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding1,602,141,400

10 Day Avg. Volume51

30 Day Avg. Volume36

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR News

Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib

Takeda (TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib, an investigational, next-generation, highly...

14h ago

TAK

Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib

Takeda (TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib, an investigational, next-generation, highly...

14h ago

TAK

Ginkgo Bioworks, Apheris announce kick off of Antibody Developability Consortium

Ginkgo Datapoints (DNA) and Apheris announced that the Antibody Developability Consortium has kicked off with its founding members....

2d ago

DNA

TAK

Keros Therapeutics to receive $20M development milestone payment from Takeda

Keros Therapeutics (KROS) announced that it expects to receive a $20 million development milestone payment under the terms...

2d ago

TAK

KROS

Innovent Biologics announces expansion of global Phase 3 MarsLight-11 trial

Innovent Biologics (IVBXF) announces expansion of the global Phase 3 MarsLight-11 trial, which is evaluating IBI363 in patients...

3d ago

TAK

Takeda announces FDA acceptance of zasocitinib under priority review

Takeda (TAK) announced that the FDA accepted its new drug application, or NDA, under priority review for zasocitinib...

17d ago

TAK

Takeda announces publication of data from Phase 3 studies of oveporexton

Takeda (TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating...

22d ago

TAK

Protagonist Therapeutics announces $300M share repurchase program

Protagonist Therapeutics (PTGX) announced that its board of directors has authorized a share repurchase program under which the...

22d ago

JNJ

TAK

Keros Therapeutics announces $5M share repurchase program after Takeda payment

Keros Therapeutics (KROS) announced that its board of directors has approved a $5M share repurchase program of the...

22d ago

TAK

KROS

Trump Trade: President warns communities against rejecting data centers

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

29d ago

AZN

LLY

Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers

Analyst Koichi Mamegano of Bank of America Securities reiterated a Buy rating on Takeda Pharmaceutical Co, boosting the...

2M ago

TAK

Mamegano Reiterates Buy on Takeda as Q1 Beat and Pipeline Progress Support Unchanged Price Objective

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co. The...

2M ago

TAK

TAKP34 FAQ

What was Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s price range in the past 12 months?

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR lowest stock price was R$65.09 and its highest was R$100.00 in the past 12 months.

What is Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s market cap?

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s market cap is R$304.64B.

When is Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s upcoming earnings report date?

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s upcoming earnings report date is Oct 29, 2026 which is in 28 days.

How were Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s earnings last quarter?

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR released its earnings results on Jul 30, 2026. The company reported R$0.002 earnings per share for the quarter.

Is Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR overvalued?

According to Wall Street analysts Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR pay dividends?

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR does not currently pay dividends.

What is Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s EPS estimate?

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR have?

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR has 1,602,141,400 shares outstanding.

What happened to Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s price movement after its last earnings report?

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR reported an EPS of R$0.002 in its last earnings report. Following the earnings report the stock price went down -1.305%.

Which hedge fund is a major shareholder of Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR?

Currently, no hedge funds are holding shares in BR:TAKP34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology